Report Library
View More
Datamonitor Healthcare CV&Met: Duch...
April 17, 2025
Head and Neck Cancer Awareness Mont...
April 10, 2025
Targeting HER3 in EGFR TKI-resistan...
April 10, 2025
Bladder Cancer KOL Interview - UK
April 8, 2025
Biomedtracker / Meddevicetracker Q2...
April 7, 2025
Prostate Cancer KOL Interview - Eng...
April 7, 2025
Prostate Cancer KOL Interview - Ita...
April 7, 2025
Prostate Cancer KOL Interview - US,...
April 7, 2025
Prostate Cancer KOL Interview - US,...
April 4, 2025
Bladder Cancer KOL Interview - US, ...
March 24, 2025
Datamonitor Healthcare I&I: Heredit...
May 1, 2025
Podcast: Highlights from AAN 2025
April 30, 2025
Sjögren’s Disease Full Report Avail...
April 30, 2025
Sjögren’s Disease KOL Interview - N...
April 28, 2025
Datamonitor Healthcare I&I: Dry Eye...
April 28, 2025
Datamonitor Healthcare Oncology: Wa...
April 18, 2025
Datamonitor Healthcare Oncology: Ut...
April 18, 2025
Datamonitor Healthcare Infectious D...
April 18, 2025
2024 Deal-making Roundup
April 17, 2025
Datamonitor Healthcare I&I: Primary...
April 17, 2025
Datamonitor Healthcare CV&Met: Duch...
April 17, 2025
Head and Neck Cancer Awareness Mont...
April 10, 2025
Targeting HER3 in EGFR TKI-resistan...
April 10, 2025
Bladder Cancer KOL Interview - UK
April 8, 2025
Biomedtracker / Meddevicetracker Q2...
April 7, 2025
Prostate Cancer KOL Interview - Eng...
April 7, 2025
Prostate Cancer KOL Interview - Ita...
April 7, 2025
Prostate Cancer KOL Interview - US,...
April 7, 2025
Prostate Cancer KOL Interview - US,...
April 4, 2025
Bladder Cancer KOL Interview - US, ...
March 24, 2025
Datamonitor Healthcare I&I: Heredit...
May 1, 2025
Podcast: Highlights from AAN 2025
April 30, 2025
Sjögren’s Disease Full Report Avail...
April 30, 2025
Sjögren’s Disease KOL Interview - N...
April 28, 2025
Datamonitor Healthcare I&I: Dry Eye...
April 28, 2025
Datamonitor Healthcare Oncology: Wa...
April 18, 2025
Datamonitor Healthcare Oncology: Ut...
April 18, 2025
Datamonitor Healthcare Infectious D...
April 18, 2025
2024 Deal-making Roundup
April 17, 2025
Datamonitor Healthcare I&I: Primary...
April 17, 2025
Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 5/1/25 | Genmab (GMAB) | Epkinly for Follicular Lymphoma (FL) | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/26/25 | Pfizer (PFE) | Sasanlimab for Bladder Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/26/25 | Protara (TARA) | TARA-002 for Bladder Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/25/25 | Abivax (ABVX) | Obefazimod for Ulcerative Colitis (UC) | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/25/25 | ALX Oncology (ALXO) | Evorpacept for Head and Neck Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 04/01/2025 | Subscribers Only | Subscribers Only | Company - Divestment/Spinoff |
| 04/05/2025 | Subscribers Only | Subscribers Only | Trial Data - Other |
| 04/24/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 04/28/2025 | Subscribers Only | Subscribers Only | Trial Data - Top-Line Results |
| 04/28/2025 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |